Vytrus Biotech, S.A. (BME:VYT)
17.00
+0.60 (3.66%)
At close: Jul 17, 2026
Vytrus Biotech Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 6.75 | 5.06 | 1.1 | 0.72 | 2.57 |
Short-Term Investments | 0.13 | 0 | 0 | 0 | 0 |
Cash & Short-Term Investments | 6.88 | 5.06 | 1.11 | 0.72 | 2.57 |
Cash Growth | 36.01% | 357.62% | 52.54% | -71.78% | 17.37% |
Accounts Receivable | 1.96 | 1.24 | 0.71 | 0.46 | 0.42 |
Other Receivables | 0.25 | 0.08 | - | - | 0.03 |
Total Trade Receivables | 2.21 | 1.32 | 0.71 | 0.46 | 0.46 |
Inventory | 1.26 | 1.06 | 0.56 | 0.43 | 0.53 |
Other Current Assets | 0.08 | 0.02 | 0.07 | 0.07 | 0.02 |
Total Current Assets | 5.39 | 3.79 | 2.45 | 1.68 | 1.82 |
Net Property, Plant & Equipment | 1.68 | 0.86 | 0.93 | 1.03 | 0.68 |
Other Intangible Assets | 9.91 | 8.15 | 3.63 | 3.15 | 5.67 |
Long-Term Investments | 0.21 | 0.17 | 0.09 | 0.07 | 0.08 |
Other Long-Term Assets | 2.53 | 2.32 | 2.22 | 2.07 | 1.81 |
Total Assets | 14.66 | 11.13 | 9.31 | 8 | 7.18 |
Accounts Payable | 0.1 | 0.2 | - | - | 0.33 |
Accrued Expenses | 0.5 | 0.34 | - | - | 0.16 |
Short-Term Debt | 0.86 | 0.97 | 0.49 | 0.74 | 0.7 |
Unearned Revenue | - | 0 | - | - | - |
Other Current Liabilities | 2.14 | 1.06 | 0.51 | 0.53 | 0.59 |
Total Current Liabilities | 1.78 | 1.25 | 1 | 1.27 | 0.81 |
Long-Term Debt | 3.09 | 3.98 | 2.37 | 1.29 | 3.08 |
Other Long-Term Liabilities | 1.03 | 0.59 | 0.66 | 0.69 | 0.59 |
Total Long-Term Liabilities | 2.58 | 2.59 | 3.03 | 1.98 | 2.13 |
Total Liabilities | 4.35 | 3.84 | 4.02 | 3.25 | 2.93 |
Common Stock | 0.08 | 0.08 | - | - | 0.07 |
Treasury Stock | -0.52 | -0.28 | - | - | -0.23 |
Additional Paid-in Capital | 4.63 | 4.63 | - | - | 3.52 |
Accumulated Other Comprehensive Income | 0.32 | 0.16 | 0.25 | 0.09 | 0.1 |
Retained Earnings | 8.72 | 4.41 | - | - | 1.13 |
Total Common Shareholders' Equity | 9.99 | 7.14 | 5.04 | 4.66 | 4.15 |
Shareholders' Equity | 10.31 | 7.29 | 5.29 | 4.75 | 4.25 |
Total Liabilities & Equity | 14.66 | 11.13 | 9.31 | 8 | 7.18 |
Total Debt | 3.95 | 4.95 | 2.85 | 2.02 | 3.77 |
Net Cash (Debt) | 2.93 | 0.1 | -1.75 | -1.3 | -1.21 |
Net Cash Growth | 2704.82% | - | - | - | - |
Net Cash Per Share | 0.38 | 0.01 | -0.25 | -0.18 | -0.17 |
Book Value | 9.99 | 7.14 | 5.04 | 4.66 | 4.15 |
Book Value Per Share | 1.31 | 0.93 | 0.71 | 0.66 | 0.59 |
Tangible Book Value | 0.08 | -1.01 | 1.42 | 1.51 | -1.52 |
Tangible Book Value Per Share | 0.01 | -0.13 | 0.20 | 0.21 | -0.22 |